Suicidal Behaviours During Efavirenz Treatment in HIV Positive Patients

Kaynakça (10)

1. Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression: a systematic review of interventions. Psychology Health and Medicine. 2011;16:493-527
2. Gazzard BG. Efavirenz in the management of HIV infection. Int J Clin Pract. 1999;53:60-4
3. O’Mahony SM, Myint AM, Steinbusch H, Leonard BE. Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation. 2005;12:293-8
4. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-5
5. Haller DL, Miles DR. Suicidal ideation among psychiatric patients with HIV: psychiatric morbidity and quality of life. AIDS Behav. 2003;7:101-8
6. Fumaz CR1, Muñoz-Moreno JA, Moltó J, Negredo E, Ferrer MJ, Sirera G, Pérez-Alvarez N, Gómez G, Burger D, Clotet B. Longterm neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr. 2005;15;38:560-5
7. Harding R, Lampe FC, Norwood S, Date HL, Clucas C, Fisher M, Sherr L. Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sexually Transmitted Infections. 2010;86:520-4
8. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy. 2002;22:930-3
9. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-5
10. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006;42:401-7.